Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.

30 June, 2021

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

24 June, 2021

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.

14 June, 2021

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

The global Alzheimer’s Association round robin study on plasma amyloid β methods.

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.

Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Sex differences in off-target binding using tau positron emission tomography.

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

A multicenter comparison of [¹⁸F]flortaucipir, [18F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.

Four distinct trajectories of tau deposition identified in Alzheimer’s disease.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.

A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [¹⁸F]flutemetamol amyloid PET images.

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.

Biomarker testing in MCI patients-deciding who to test.

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.